Macular Pigment and Visual Performance in Glaucoma Patients

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Glaucoma

In brief

The purpose of this study is to determine cross-sectional relationships between macular pigment optical density (MPOD) and visual performance in glaucoma. Additionally, the investigators wish to determine the effect of lutein, zeaxanthin, and mesozeaxanthin supplementation on MPOD and visual performance in glaucoma patients.

Key facts

Study ID

NCT03959592

Run by

Felipe Medeiros, MD

People needed

8

Starts

2019-08-21

Expected to finish

2021-11-09

Last updated by the study team

2023-01-03

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• glaucoma diagnosis: To be considered glaucomatous, patients will be required to have: (1) history of elevated intraocular pressure (IOP; over 21 mmHg); (2) at least two consecutive and reliable standard automated perimetry (SAP) examinations with either a pattern standard deviation (PSD) outside the 95% normal limits or a glaucoma hemifield test (GHT) result outside the 99% normal limits; and/or glaucomatous optic neuropathy.
• between the ages of 18 and 75 years,
• must be able and willing to provide signed informed consent and follow study instructions.

You may not qualify if…

• no systemic disease, no other ocular disease

Where it is running

• Duke University Eye Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.